尽管内部交易, 但在分析师升级后, 阿吉奥斯制药股价下跌. Agios Pharmaceuticals shares dropped after analyst upgrades despite insider sales.

Agios Pharmaceuticals股价因分析师上调而下跌，摩根大通将目标从31.00美元上调至36.00美元。 Agios Pharmaceuticals shares fell on analyst upgrades, with JPMorgan raising its target to $36.00 from $31.00. 尽管有来自花旗集团和Leerink Partners等公司的升级, 但该股票仍具有"持仓"评价以及42.67美元的平均目标. Despite the upgrades from firms like Citigroup and Leerink Partners, the stock has a consensus "hold" rating and an average target of $42.67. 生物制药公司专注于癌症代谢疗法. Recent insider sales have also occurred, and the biopharmaceutical company focuses on metabolic therapies for cancer.